Protocol Ledger

NCT03876769 · Phase II · ACTIVE NOT RECRUITING

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Interventional Phase II clinical trial protocol NCT03876769 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-24 Enrollment: 121 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03876769
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03876769
Protocol FieldVerified Registry Value
NCT IdentifierNCT03876769
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment121 participants (ACTUAL)
Registered Start Date2019-06-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI